Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.66 |
| ▸ | KIT | P10721 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 4/20 | 0.65 |
| ▸ | LYN | P07948 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 5/20 | 0.64 |
| ▸ | ITK | Q08881 | 3/20 | 0.64 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.63 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434693 | 0.89 | BTK (0.64) | BTKKITFLT3LCKLYN | |
| SCHEMBL6430310 | 0.86 | BTK (0.64) | BTKKITFLT3LCKLYN | |
| SCHEMBL7697145 | 0.85 | BTK (0.62) | BTKKITFLT3LCKLYN | |
| SCHEMBL6645874 | 0.85 | BTK (0.85) | BTKKITFLT3LCKLYN | |
| SCHEMBL6431679 | 0.85 | BTK (0.61) | BTKFLT3LCKLYNEGFR | |
| SCHEMBL5802228 | 0.85 | BTK (0.58) | BTKKITFLT3LCKLYN | |
| Acetic Acid SCHEMBL6461687 | 0.84 | BTK (0.64) | BTKKITFLT3LCKLYN | |
| SCHEMBL5801655 | 0.84 | BTK (0.71) | BTKKITFLT3LCKLYN | |
| SCHEMBL5803152 | 0.84 | BTK (0.70) | BTKFLT3LCKLYNEGFR | |
| SCHEMBL7144296 | 0.84 | BTK (0.73) | BTKFLT3LCKLYNEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | BTK 42/4885KIT 330/4885FLT3 335/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | BTK 1020/4885KIT 445/4885FLT3 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.